ANI Pharma CEO sells 55,000 shares in open trade

ANI Pharmaceuticals President and CEO Nikhil Lalwani reported an open-market sale of 55,000 shares of Common Stock on May 11, 2026, at a weighted average price of $77.57 per share.

Rhea-AI Filing Summary

ANI Pharmaceuticals President and CEO Nikhil Lalwani reported an open-market sale of 55,000 shares of Common Stock on May 11, 2026, at a weighted average price of $77.57 per share. The shares were sold in multiple trades at prices ranging from $76.21 to $80.38. Following this transaction, Lalwani directly holds 349,889 shares of ANI Pharmaceuticals Common Stock.

Insider Trade Summary

Net Seller: 55,000 shares

Net Sell 1 txn

Insider Lalwani Nikhil

Role PRESIDENT & CEO

Sold 55,000 shs ($4.27M)

Type	Security	Shares	Price	Value
Sale	Common Stock	55,000	$77.57	$4.27M

Holdings After Transaction: Common Stock — 349,889 shares (Direct)

Footnotes (1)

1. F1. The shares were sold in multiple trades at prices ranging from $76.21 to $80.38. The price reported above reflects the weighted average sales price.

Key Figures

Shares sold: 55,000 shares Weighted average sale price: $77.57 per share Sale price range: $76.21–$80.38 per share +1 more

4 metrics

Shares sold 55,000 shares Open-market sale of Common Stock on May 11, 2026

Weighted average sale price $77.57 per share Average price across multiple trades on May 11, 2026

Sale price range $76.21–$80.38 per share Range of prices for individual trades within the sale

Shares held after transaction 349,889 shares Direct Common Stock holdings following the reported sale

Key Terms

open-market sale, weighted average sales price, Common Stock, Form 4

4 terms

open-market sale financial

"reported an open-market sale of 55,000 shares of Common Stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sales price financial

"The price reported above reflects the weighted average sales price"

Common Stock financial

"open-market sale of 55,000 shares of Common Stock on May 11, 2026"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"reported in the Form 4 filing"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ANI Pharmaceuticals (ANIP) CEO Nikhil Lalwani report in this Form 4?

ANI Pharmaceuticals CEO Nikhil Lalwani reported an open-market sale of 55,000 shares of Common Stock. The transaction occurred on May 11, 2026, and reflects a routine Section 16 insider trading disclosure for his personal holdings.

How many ANI Pharmaceuticals (ANIP) shares did the CEO sell and at what price?

Nikhil Lalwani sold 55,000 shares of ANI Pharmaceuticals Common Stock at a weighted average price of $77.57 per share. The sales were executed in multiple trades within a price range from $76.21 to $80.38.

How many ANI Pharmaceuticals (ANIP) shares does the CEO hold after this sale?

After selling 55,000 shares, ANI Pharmaceuticals CEO Nikhil Lalwani directly holds 349,889 shares of Common Stock. This post-transaction holding reflects his remaining direct equity stake as reported in the Form 4 filing.

What does the price range in the ANI Pharmaceuticals (ANIP) CEO’s sale mean?

The Form 4 notes the shares were sold in multiple trades between $76.21 and $80.38 per share. The reported $77.57 figure is the weighted average sales price across those individual transactions executed on May 11, 2026.

Was the ANI Pharmaceuticals (ANIP) CEO’s transaction a buy or a sell?

The transaction reported by ANI Pharmaceuticals CEO Nikhil Lalwani is a sale. It is classified as an open-market sale of 55,000 shares of Common Stock, coded “S” in the Form 4, indicating a disposition rather than an acquisition.

Is there any indication this ANI Pharmaceuticals (ANIP) sale was done through multiple trades?

Yes. A footnote explains that the 55,000 shares were sold in multiple trades. Those individual trades occurred at prices ranging from $76.21 to $80.38 per share, with $77.57 reported as the weighted average sales price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/13/2026 - 04:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lalwani Nikhil

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

104 CARNEGIE CENTER, SUITE 300

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/11/2026		S		55,000	D	$77.57(1)	349,889	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold in multiple trades at prices ranging from $76.21 to $80.38. The price reported above reflects the weighted average sales price.

Remarks:

	/s/ Nikhil Lalwani, by attorney-in-fact Meredith W. Cook	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)